NCT01743469

Who might be able to join this trial:

All patients must meet these criteria:

• You are willing and able to give written consent and follow the study rules and procedures.
• You are 18 years of age or older.
• You are generally able to carry out daily activities with little or no limitation due to your illness (confirm with trial site for exact fitness level required).
• Your doctor believes you are likely to live for more than 3 months.
• Your cancer has gotten worse during or after previous cancer treatment.
• Your cancer can be measured using standard imaging scans.
• Enough time has passed since your last cancer treatment before starting this trial — the exact waiting period depends on what type of treatment you had (confirm with trial site for specifics).
• Side effects from your previous cancer treatment have mostly resolved to a mild level (hair loss is an exception).
• At least 4 weeks have passed since any major surgery, or at least 7 days since a needle biopsy.
• Your kidneys are working well enough, based on blood test results.
• Your liver is working well enough, based on blood test results.
• Your bone marrow is producing enough blood cells, based on blood test results.
• Your blood clotting ability is within an acceptable range, based on blood test results.
• You are able to swallow capsules.
• If you are a woman who could become pregnant, you must have a negative pregnancy test before starting the trial.
• If you are a woman who could become pregnant, you must agree to use effective contraception during treatment and for at least 3 months after your last dose.
• If you are a man, you must agree to use a barrier method of contraception (such as a condom) during treatment and for at least 3 months after your last dose.

If you have liver cancer (hepatocellular carcinoma), you also need to meet these criteria:

• You have been diagnosed with hepatocellular carcinoma confirmed by tissue sample (a specific rare type called fibrolamellar carcinoma does not qualify).
• Your liver cancer is at an advanced stage or cannot be treated with, or has not responded to, local treatments targeting the liver.
• You have a liver tumour of at least 2 cm that shows a specific blood supply pattern on a CT or MRI scan.
• You have at least one active, blood-supplied tumour that has not been treated with local liver therapy, or one that has visibly grown after such treatment.
• Your liver is still functioning reasonably well, based on a standard liver scoring system called Child-Pugh Class A.
• You have previously been treated with a drug called sorafenib, and your cancer progressed during or after that treatment.
• Sorafenib was the last systemic (whole-body) treatment you received (local liver treatments before sorafenib are allowed, but not after; radiation to areas outside the liver after sorafenib is permitted).

If you have ovarian cancer, you also need to meet these criteria:

• You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer confirmed by tissue sample.
• Your cancer came back or got worse within 6 months of receiving a platinum-based chemotherapy treatment.
• Your cancer has progressed after up to three rounds of chemotherapy.
• You have had no more than one treatment with a therapy that targets blood vessel growth (anti-angiogenic therapy).

If you have kidney cancer (renal cell carcinoma), you also need to meet these criteria:

• You have kidney cancer that has spread to other parts of the body.
• Your kidney cancer has been confirmed by tissue or cell sample and contains a specific type called clear cell.
• You have previously been treated with at least one drug that targets blood vessel growth (a VEGF inhibitor).
• Your cancer has gotten worse within the 6 months before joining the trial.
• You have had no more than two targeted therapy treatments for advanced or metastatic kidney cancer.

If you have stomach cancer (gastric carcinoma), you also need to meet these criteria:

• You have been diagnosed with a specific type of stomach or gastroesophageal junction cancer called adenocarcinoma, confirmed by tissue or cell sample.
• Your cancer cannot be removed by surgery, has spread, or has come back after surgery that aimed to cure it.
• Your cancer has gotten worse after one round of chemotherapy that included specific drug types (fluoropyrimidine and platinum), with or without